Table 1.
Demographics of the study participants undergoing treatment for early stage breast cancer (N = 58).
| Variable | N (%) or mean ± SD (range) |
|---|---|
| Age | 51.48 ± 10.52 (23, 69) |
| Race | |
| African-American | 19 (32.8%) |
| Caucasian | 39 (67.2%) |
| Others | 0 (0.0%) |
| BMI (kg/m2) | 30.27 ± 7.31 (19.11, 54.34) |
| Current smoking status | |
| Yes | 11 (19.0%) |
| No | 47 (81.0%) |
| Stage | |
| I | 16 (27.6%) |
| IIA | 26 (44.8%) |
| IIB | 11 (19.0%) |
| IIIA | 5 (8.6%) |
| Triple negative | |
| Yes | 19 (32.8%) |
| No | 39 (67.2%) |
| Neoadjuvant | |
| Yes | 6 (10.3%) |
| No | 52 (89.7%) |
| Radiation treatment | |
| Yes | 44 (75.9%) |
| No | 14 (24.1%) |
| Chemotherapy regimen | |
| AC | 1 (1.7%) |
| CMF | 2 (3.4%) |
| TAC | 25 (43.1%) |
| TC | 19 (32.8%) |
| TCH | 11 (19.0%) |
| BFI (Total) | 2.25 ± 2.71 (0, 9.5) |
| PSS | 2.15 ± 0.35 (1.5, 3) |
| HADS | 5.67 ± 2.69 (0, 12) |
| BPI (Pain severity) | 1.69 ± 2.27 (0, 7) |
Abbreviations: AC, doxorubicin (Adriamycin), cyclophosphamide (Cytoxan); BFI, brief fatigue inventory; BMI, body mass index; BPI, brief pain inventory; CMF, cyclophosphamide, methotrexate and fluorouracil; HADS, hospital anxiety and depression scale; PSS, perceived stress scale; SD, standard deviation; TAC, docetaxel (Taxotere), doxorubicin (Adriamycin), cyclophosphamide (Cytoxan); TC, docetaxel (Taxotere) and cyclophosphamide (Cytoxan); TCH, docetaxel (Taxotere), carboplatin (Paraplatin), trastuzumab (Herceptin).